NNZ-2566

DRUG8 trials

Sponsors

Neuren Pharmaceuticals Limited

Conditions

Brain InjuriesBrain Injuries, TraumaticConcussionFragile X SyndromeRett Syndrome

Phase 1

Safety Study of NNZ-2566 in Healthy Female Subjects

CompletedNCT00961779

Neuren Pharmaceuticals LimitedBrain Injuries, Traumatic

Start: 2010-03-31End: 2010-09-30Updated: 2014-10-07

Safety Study of NNZ-2566 in Healthy Subjects, Following Oral Administration

CompletedNCT01420042

Neuren Pharmaceuticals LimitedBrain Injuries, Traumatic

Start: 2012-02-29End: 2012-09-30Updated: 2012-11-22

Phase 2

Study of NNZ-2566 in Patients With Traumatic Brain Injury

CompletedNCT00805818

Neuren Pharmaceuticals LimitedBrain Injuries

Start: 2010-04-30End: 2016-01-31Updated: 2018-02-05

Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC

CompletedNCT01366820

Neuren Pharmaceuticals LimitedBrain Injuries

Start: 2013-02-28End: 2016-01-31Updated: 2018-02-05

A Safety Study of NNZ-2566 in Patients With Rett Syndrome

CompletedNCT01703533

Neuren Pharmaceuticals LimitedRett Syndrome

Start: 2013-03-31End: 2014-09-30Updated: 2018-02-05

A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome

CompletedNCT01894958

Neuren Pharmaceuticals LimitedFragile X Syndrome

Start: 2014-01-31End: 2015-10-31Updated: 2018-02-05

A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)

TerminatedNCT02100150

Neuren Pharmaceuticals LimitedConcussion

Start: 2014-09-30End: 2016-06-30Updated: 2018-02-05

A Safety Study of NNZ-2566 in Pediatric Rett Syndrome

CompletedNCT02715115

Neuren Pharmaceuticals LimitedRett Syndrome

Start: 2016-03-31End: 2017-01-05Updated: 2020-08-14

Related Papers

Exposure-Response Efficacy Modeling to Support Trofinetide Dosing in Individuals with Rett Syndrome.

2024-02-163 citations

The EEG Ictal-Interictal Continuum-A Metabolic Roar But a Whimper of a Functional Outcome.

2019-06-144 citations

Continuous Electroencephalography After Moderate to Severe Traumatic Brain Injury

Critical Care Medicine2019-01-1971 citations

A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial.

2014-09-038 citations